Cullgen Receives $16 Million Series A Investment to Advance Pipeline of Targeted Protein Degraders

SAN DIEGO–(BUSINESS WIRE)–Cullgen Inc. (Cullgen), a biotechnology company dedicated to the development of targeted protein degraders for the treatment of diseases lacking effective therapeutic approaches, today announced it has received a $16 million Series A financing from two prominent international venture capital firms, Sequoia Capital China (Sequoia) and Highlight Capital (HC). The financing will support the development of Cullgen?s internal pipeline of targeted protein degraders in onco